[Federal Register Volume 71, Number 72 (Friday, April 14, 2006)]
[Notices]
[Pages 19534-19535]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-5530]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive License: Therapeutics for the 
Treatment of Neurodegenerative Disorders

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 
404.7(a)(1)(i), announces that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license to practice the inventions embodied in: 1. E-177-
1990/2-US-01, ``Activity-dependent Neurotrophic Factor'' by Douglas E. 
Brenneman and Illana Gozes, patent number 5,767,240 (issue date June 
16, 1998); 2. E-177-1990/3-US-01, ``Activity-dependent Neurotrophic 
Factor'' by Douglas E. Brenneman and Illana Gozes, patent number 
6,174,862 (issue date January 16, 2001); 3. E-177-1990/1-PCT-01, 
``Activity-dependent Neurotrophic Factor'' by Douglas E. Brenneman and 
Illana Gozes, patent application number PCT/US92/03109 (filing date 
April 22, 1992) and all related foreign patent applications; 4. E-177-
1990/3-PCT-02, ``Activity-dependent Neurotrophic Factor'' by Douglas E. 
Brenneman and Illana Gozes, patent application number PCT/US95/12929 
(issue date October 16, 1995) and all related foreign patent 
applications; 5. E-209-2001/0-US-01, ``Neurotrophic Components of the 
ADNF I Complex'' by Brenneman et al., patent application number 60/
322,760 (filing date September 12, 2001); 6. E-209-2001/2-US-01, 
``Neurotrophic Components of the ADNF I Complex'' by Brenneman et al., 
patent application number 60/371,961 (filing date April 10, 2002); 7. 
E-209-2001/1-PCT-01, ``Neurotrophic Components of the ADNF I Complex'' 
by Brenneman et al., patent application number PCT/US02/29146 (filing 
date September 12, 2002); 8. E-209-2001/1-US-02, ``Neurotrophic 
Components of the ADNF I Complex'' by Brenneman et al., patent 
application number 10/489,515 (filing date March 11, 2004); to Allon 
Therapeutics, having a place of business in Vancouver, BC, Canada. The 
patent rights in these inventions have been assigned to the United 
States of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to therapeutics for the treatment of 
human neurodegenerative diseases.

DATES: Only written comments and/or license applications which are 
received by the National Institutes of Health on or before June 13, 
2006 will be considered.

ADDRESSES: Requests for copies of the patent and/or patent 
applications, inquiries, comments and other materials relating to the 
contemplated exclusive license should be directed to: John Stansberrry, 
PhD., Technology Licensing Specialist, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, MD 20852-3804; Telephone: (301) 435-5236; Facsimile: (301) 
402-0220; E-mail: [email protected].

SUPPLEMENTARY INFORMATION: Neuronal cell death has been associated with 
a variety of diseases and conditions, including Alzheimer's, AIDS-
related dementia, Huntington's disease, and Parkinson's disease to name 
a few. Neuronal cell death has also been associated with developmental 
retardation and learning impairments that have lifelong effects on 
individuals diagnosed with these conditions.
    This invention discloses pharmaceutical compositions and methods of 
using Activity Dependent Neurotrophic Factor I (ADNF I) complex 
polypeptides which have been shown to prevent neuronal cell death. ADNF 
polypeptides are secreted by astroglial cells in the presence of 
vasoactive intestinal peptide (VIP). These new ADNF I complex 
polypeptides are effective for reducing neuronal cell death, for 
reducing oxidative stress, for reducing condition(s) associated with 
fetal alcohol syndrome in a subject, for enhancing learning and memory, 
both

[[Page 19535]]

pre- and post-natally, and for other conditions.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establish that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: April 6, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E6-5530 Filed 4-13-06; 8:45 am]
BILLING CODE 4140-01-P